Practice, efficacy and cost of staging Suspected non-small cell luna cancer: a retrospective study in two Dutch hospital

Herder, G. J. M.; Verboom, P.; Smit, E. F.; van Velthoven, P. C. M.; van den Bergh, J. H. A. M.; Colder, C. D.; van Mansom, I.; van Mourik, J. C.; Postmus, P. E.; Teule, G. J. J.; Hoekstra, O. S.
January 2002
Thorax;Jan2002, Vol. 57 Issue 1, p11
Academic Journal
Background: A study was undertaken to investigate the clinical practice, yield, and costs of preoperative staging in patients with suspected NSCLC and to obtain baseline data for prospective studies on the cost effectiveness of 14F-fluorodeoxyglucose positron emission tomography in the management of these patients. Methods: A retrospective study of the medical records of all patients with suspected NSCLC was performed during a 2 year interval (1993-4) in an academic and a large community hospital. Results: Three hundred and ninety five patients with suspected NSCLC were identified; 58 were deemed to be medically inoperable and 337 patients proceeded to the staging process. Staging required a mean (SD) of 5.1 (1 .5) diagnostic tests per patient (excluding thoracotomy) carried out over a median period of 20 days (IQR 10-31). Many of the tests (including both invasive and non-invasive) were done because previous imaging tests had suggested metastases, and in most cases the results of initial tests proved to be false positives. After clinical staging, 168 patients were considered to be resectable [stage I/II] and 144 patients underwent surgery with curative intent. At surgery 33 patients{23% of those who underwent surgery} were found to have irresectable lesions and 19 (13%) had a benign lesion. Surgery was also considered to be futile in 22 patients (15%) who developed metastases or local recurrence within 12 months following radical surgery. Hospital admission was responsible for most of the costs. Conclusion: In many patients staging involved considerable effort in terms of the number of diagnostic tests, the duration of the staging period and the cost, with limited success in preventing futile surgery. Failures relate to the quality of diagnostic preparation at every level of the TNM staging system.


Related Articles

  • Surgery in limited-disease small-cell lung cancer. Koul, Parvaiz A. // Lung India;Jan-Mar2012, Vol. 29 Issue 1, p2 

    The author reflects on the abandonment of surgery as a treatment of choice for patients with limited-disease small-cell lung cancer (LD-SCLC) due to the result of a randomized trial which revealed a survival difference between surgery and radiotherapy. An overview of some studies which show that...

  • Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Clegg, A.; Scott, D. A.; Hewitson, P.; Sidhu, M.; Waugh, N. // Thorax;Jan2002, Vol. 57 Issue 1, p20 

    Background: Lung cancer remains a devastating disease with few effective treatment options. Recent developments in chemotherapy have led to cautious optimism. This paper reviews the evidence on the clinical and cost effectiveness of four of the new generation drugs for patients with lung cancer....

  • FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eschmann, M.; Friedel, G.; Paulsen, F.; Budach, W.; Harer-Mouline, C.; Dohmen, M.; Bares, R. // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 6, p804 

    The aim of this study was to evaluate positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) for the staging of non-small cell lung cancer (NSCLC) before combined neoadjuvant, i.e. preoperative, radio-chemotherapy (RCT). From November 1998 until September 2001, 101 patients...

  • Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment. Kumar, D. Santhosh; Noronha, Vanita; Joshi, Amit; Jain, Hasmukh; Prabhash, Kumar // Indian Journal of Medical & Paediatric Oncology;Jan-Mar2014, Vol. 35 Issue 1, p75 

    Carcinomatous meningitis or meningeal carcinomatosis is seen in up to 5% of patients of metastatic non-small cell lung cancer. However, isolated carcinomatous meningitis without brain parenchymal metastasis is less common. Patients with carcinomatous meningitis have limited treatment options....

  • The mediastinal staging accuracy of 18F-Fluorodeoxyglycose Positron Emission Tomography / Computed Tomography in non-small cell lung cancer with variable time intervals to surgery. Booth, Karen; Hanna, Gerard G.; McGonigle, Niall; McManus, Kieran G.; McGuigan, James; O'Sullivan, Joe; Lynch, Tom; McAleese, Jonathan // Ulster Medical Journal;May2013, Vol. 82 Issue 2, p75 

    Background: PET/CT scanning can determine suitability for curative therapy and inform decision making when considering radical therapy in patients with non-small cell lung cancer (NSCLC). Metastases to central mediastinal lymph nodes (N2) may alter such management decisions. We report a 2 year...

  • Lung cancer: new opportunities—changing algorithm in staging. Weder, W. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p28 

    The article discusses new opportunities in the treatment of non-small-cell lung cancer (NSCLC). It states that many studies have examined the use of computed tomography (CT) and positron emission tomography (PET) for staging NSCLC over the years. It mentions that imaging modalities alone such as...

  • Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Askoxylakis, Vasileios; Dinkel, Julien; Eichinger, Monika; Stielyjes, Bram; Sommer, Gregor; Strauss, Ludwig G; Dimitrakopoulou-Strauss, Antonia; Kopp-Schneider, Annette; Haberkorn, Uwe; Huber, Peter E; Bischof, Marc; Debus, Jürgen; Thieke, Christian // Radiation Oncology;2012, Vol. 7 Issue 1, p157 

    Background: Radiotherapy, preferably combined with chemotherapy, is the treatment standard for locally advanced, unresectable non-small cell lung cancer (NSCLC). The tumor response to different therapy protocols is variable, with hypoxia known to be a major factor that negatively influences...

  • An Observational Study of Circulating Tumor Cells and 18F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. Nair, Viswam S.; Keu, Khun Visith; Luttgen, Madelyn S.; Kolatkar, Anand; Vasanawala, Minal; Kuschner, Ware; Bethel, Kelly; Iagaru, Andrei H.; Hoh, Carl; Shrager, Joseph B.; Loo Jr, Billy W.; Bazhenova, Lyudmila; Nieva, Jorge; Gambhir, Sanjiv S.; Kuhn, Peter // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Introduction: We investigated the relationship of circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) with tumor glucose metabolism as defined by 18F-fluorodeoxyglucose (FDG) uptake since both have been associated with patient prognosis. Materials & Methods: We performed a...

  • Lenograstim + chemo for SCLC: cost effectiveness "finely balanced.".  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p9 

    The article discusses research being done on the cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer (SCLC). It references a study by L. Bojke and colleagues in the April 15, 2006 issue of "PharmacoEconomics."...


Read the Article


Sign out of this library

Other Topics